Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 354 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Mask Clear all
Completed Phase 2 Interventional Results available

The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age

NCT02636868
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Lucinactant delivered via investigational delivery device, nCPAP
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
26 Weeks to 32 Weeks
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 23, 2026, 7:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

An Investigation of Attentional and Inhibitory Processes During Active Visual Search in Humans

NCT06587113
View directory record Official record
Conditions
Eye Movements, Attention, Executive Function
Interventions
Contour Search Task, Stop signal Task, Useful field of View, Attentional capture search task
Other · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea

NCT01629862
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Diabetes Mellitus
Interventions
Continuous positive airway pressure, Sham continuous positive airway pressure
Device
Lead sponsor
Sanjay R Patel
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 1 Interventional

DFMO in Children With Type 1 Diabetes

NCT02384889
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Difluoromethylornithine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 40 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Indianapolis, Indiana • Buffalo, New York • Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG

NCT02829996
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD, latanoprost 0.005% QD, latanoprost 0.0025% QD
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

NCT04423718
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 23, 2026, 7:02 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Investigating the Evolutionary Impact of Metabolic Flexibility on Physical Activity-Dependent BDNF and Cognition: Insights From the Val66Met Polymorphism

NCT07218497
View directory record Official record
Conditions
Cognition, BDNF
Interventions
d-beta-hydroxybutrate, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 35 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 23, 2026, 7:02 AM EDT
Active, not recruiting Phase 2 Interventional

Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

NCT03478215
View directory record Official record
Conditions
Renal Transplantation, Mesenchymal Stem Cells
Interventions
Mesenchymal Stromal Stem Cells (MSCs) Infusion, Normal Saline (Placebo) Infusion
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Cloth Face Coverings as Source Control Under Laboratory and Simulated Field Conditions

NCT05216939
View directory record Official record
Conditions
Masks
Interventions
Flannel mask with ear loops, Flannel mask with ties, Twill mask with ear loops, Twill mask with ties
Other
Lead sponsor
Emory University
Other
Eligibility
6 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

NCT03858894
View directory record Official record
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
13
States / cities
Los Angeles, California • Danbury, Connecticut • Brooksville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis

NCT01243983
View directory record Official record
Conditions
Noninfectious Uveitis
Interventions
LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 23, 2026, 7:02 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446
View directory record Official record
Conditions
Refractory or Unexplained Chronic Cough
Interventions
NOC-110, Placebo
Drug · Other
Lead sponsor
Nocion Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
68
States / cities
Foley, Alabama • Scottsdale, Arizona • Tempe, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)

NCT03610646
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
MYL-1701P, Eylea
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Sacramento, California • St. Petersburg, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 4 Interventional Results available

Serratus Plane Versus Paravertebral Nerve Blocks for Breast Surgery

NCT03860974
View directory record Official record
Conditions
Breast Surgery
Interventions
Serratus Plane block (single injection), Paravertebral block (single injection)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 23, 2026, 7:02 AM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

NCT06321302
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema

NCT03622593
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aflibercept, Faricimab, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
50
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

NCT01922128
View directory record Official record
Conditions
Nonexudative Age-related Macular Degeneration
Interventions
MC-1101, Placebo
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Not applicable Interventional

Web-Based Weight Loss & Weight Maintenance Intervention for Older Rural Women, Also Known as Women Weigh-in for Wellness

NCT01307644
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Experimental: Web-based only (WO) weight intervention, Experimental: WO plus peer-led discussion board (WD), Experimental: WO & professional email counseling (WE)
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management

NCT00801892
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Diabetes Mellitus, Type 2
Interventions
Continuous Positive Airway Pressure (CPAP), Sham- Continuous Positive Airway Pressure (Sham-CPAP)
Device
Lead sponsor
Eileen R. Chasens
Other
Eligibility
40 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

NCT04126317
View directory record Official record
Conditions
Neovascular (Wet) Age-Related Macular Degeneration
Interventions
aflibercept, High-dose aflibercept
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
45
States / cities
Phoenix, Arizona • Sun City, Arizona • Encino, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 23, 2026, 7:02 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

NCT06770933
View directory record Official record
Conditions
Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Interventions
VX-01, Placebo
Drug
Lead sponsor
Vantage Biosciences Ltd
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Beverly Hills, California • Palo Alto, California • Santa Barbara, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

NCT04784091
View directory record Official record
Conditions
Blepharitis
Interventions
TP-03, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Northridge, California • San Ramon, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 1Phase 2 Interventional

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

NCT01654484
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost, Placebo
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Newport Beach, California • Deerfield Beach, Florida • Largo, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 23, 2026, 7:02 AM EDT
Completed Phase 3 Interventional

A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness

NCT06803654
View directory record Official record
Conditions
Ocular Redness
Interventions
BTOS-HA, Lumify®
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
11
States / cities
Glendale, California • Newport Beach, California • Northbrook, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 23, 2026, 7:02 AM EDT